(4R,6R)-tert-Butyl-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate

We are (4R,6R)-tert-Butyl-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate CAS:125995-13-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  (4R,6R)-tert-Butyl-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate
CAS.NO:125995-13-3
Synonyms:(4R-cis)-1,1-dimethylethyl-[6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetate
Atorvastatin Intermediate 1
3-dioxane-4-acetate
tert-Butyl 2-[(4R,6R)-6-(2-Aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetate
(4R,6R)-Tert-Butyl-6-(2-Aminoe

Molecular Formula: C14H27NO4
Molecular Weight:273.36800

Physical and Chemical Properties:
Density: 0.992 g / cm3
Boiling point: 339.8ºC at 760 mmHg
Flash point: 96.8ºC
Refractive index: 1.454-1.456

Specification:
Appearance:Light yellowish oily liquid
Purity:≥98.0%

Packing:20KG fluoride bottle
Storage:Closed in a cool and dry environment.
Application: Medicinal intermediate, the main raw material of the lipid-lowering drug atorvastatin calcium.Intermediates of Atorvastatin CAS:134523-00-5.

Related News: There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space.trans-4-ciclohexil-L-prolina CAS:103201-78-1 There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space.N-Hydroxymethyl-3,4,5,6-tetrahydrophthalimide There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space.863127-76-8 Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday.Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday.